Premium
OUTCOME FOLLOWING STANDARDIZED 185 MBq DOSE 131 I THERAPY FOR GRAVES' DISEASE
Author(s) -
WATSON A. B.,
BROWNLIE B. E. W.,
FRAMPTON C. M.,
TURNER J. G.,
ROGERS T. G. H.
Publication year - 1988
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1988.tb03683.x
Subject(s) - medicine , antithyroid drugs , graves' disease , thyroidectomy , radioiodine therapy , disease , endocrinology , antithyroid agent , gastroenterology , thyroid , thyroid cancer
SUMMARY The clinical outcome of 199 patients with Graves' disease treated with standardized 185MBq 131 I therapy doses has been analysed. Most patients were controlled with antithyroid drugs prior to the 131 I therapy, and also received antithyroid drugs for several months following 131 I. The median follow‐up period was 5.5 years. The single 185MBq 131 I dose successfully treated 72.4% of patients. The 1,2 and 5 year hypothyroid figures were 15.5%, 19.3% and 27.3%, respectively. Previous thyroidectomy was associated with an increased hypothyroid rate. Retreatment was required by 25.6%, with 3.5% requiring more than two 131 I doses. Discriminant analysis of pretreatment variables suggests that patients with large goitres or severe disease (serum T3 > 10nmol/l) should be treated with higher doses of 131 I.